A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis

Journal of Cystic Fibrosis

Volumn 8, Issue 1, 2009, Pages 71-78

  Mayell, S J ^a   Munck, A ^b   Craig, J V ^a   Sermet, I ^c   Brownlee, K G ^d   Schwarz, M J ^e   Castellani, C ^f   Southern, K W ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e ST MARY S HOSPITAL   (United Kingdom)

^f Azienda Ospedaliera   (Italy)

Author keywords

Cystic fibrosis; Gene analysis; Management; Neonatal screening; Sweat test

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; CLINICAL PROTOCOL; CYSTIC FIBROSIS; EUROPE; GENE MUTATION; GENETIC ANALYSIS; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HUMAN; INFANT; MEDICAL ASSESSMENT; MEDICAL SPECIALIST; NEWBORN SCREENING; RESPIRATORY TRACT DISEASE; SWEAT TEST;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC SCREENING; HUMANS; INFANT, NEWBORN; MUTATION; NEONATAL SCREENING; SODIUM CHLORIDE; SWEAT;

EID: 57649155710     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2008.09.005     Document Type: Article

References (16)

1. Farrell M.P. Is newborn screening for cystic fibrosis a basic human right?. J Cyst Fibros 7 (2008) 262-265
2. Crossley J.R., Elliott R.B., and Smith P.A. Dried-blood spot screening for cystic fibrosis in the newborn. Lancet 1 8114 (Mar 3 1979) 472-474
3. Southern K.W. Newborn screening for cystic fibrosis: the practical implications. J R Soc Med 97 Suppl 44 (2004) 57-59
4. Southern K.W., Munck A., Pollitt R., Travert G., Zanolla L., Dankert-Roelse J., et al. A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros 6 1 (Jan 2007) 57-65
5. Massie R.J., Wilcken B., Van Asperen P., Dorney S., Gruca M., Wiley V., et al. Pancreatic function and extended mutation analysis in DeltaF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels. J Pediatr 137 2 (Aug 2000) 214-220
6. Castellani C., Picci L., Scarpa M., Dechecchi M.C., Zanolla L., Assael B.M., et al. Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers. Am J Med Genet 135 2 (Jun 1 2005) 142-144
7. Roussey M., Le Bihannic A., Scotet V., Audrezet M.P., Blayau M., Dagorne M., et al. Neonatal screening of cystic fibrosis: diagnostic problems with CFTR mild mutations. J Inherit Metab Dis 30 4 (Aug 2007) 613
8. Merelle M.E., Nagelkerke A.F., Lees C.M., and Dezateux C. Newborn screening for cystic fibrosis. Cochrane Database Syst Rev (Online) 3 (2001) CD001402
9. Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess (Winchester, England). 1998;2(3):i-iv, 1-88.
10. Castellani C., Cuppens H., Macek Jr. M., Cassiman J., Kerem E., Durie P., et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 7 (2008) 179-196
11. LeGrys V.A., Yankaskas J.R., Quittell L.M., Marshall B.C., and Mogayzel Jr. P.J. Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr 151 1 (Jul 2007) 85-89
12. Eng W., LeGrys V.A., Schechter M.S., Laughon M.M., and Barker P.M. Sweat-testing in preterm and full-term infants less than 6 weeks of age. Pediatr Pulmonol 40 1 (2005) 64-67
13. Parad R.B., Comeau A.M., Dorkin H.L., Dovey M., Gerstle R., Martin T., et al. Sweat testing infants detected by cystic fibrosis newborn screening. J Pediatr 147 3 (2005) S69-S72
14. Groman J.D., Hefferon T.W., Casals T., Bassas L., Estivill X., Des Georges M., et al. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet 74 1 (Jan 2004) 176-179
15. Cuppens H., Lin W., Jaspers M., Costes B., Teng H., Vankeerberghen A., et al. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest 101 2 (Jan 15 1998) 487-496
16. Peckham D., Conway S.P., Morton A., Jones A., and Webb K. Delayed diagnosis of cystic fibrosis associated with R117H on a background of 7T polythymidine tract at intron 8. J Cyst Fibros 5 1 (Jan 2006) 63-65